US pharma major Eli Lilly (NYSE: LLY) has reported positive topline data from its Phase III ATTAIN-MAINTAIN trial, showing that its oral GLP-1 candidate orforglipron helped patients maintain weight ...
RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw)SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...
Fosun is joining the fray through its subsidiary Yao Pharma, which has granted Pfizer an exclusive worldwide license to ...
Eli Lilly’s decision to pour more than $6 billion into a new pharmaceutical ingredient plant in Huntsville, Alabama, caps a ...
The City of Huntsville has taken another step toward bringing pharmaceutical giant Eli Lilly’s $6 billion facility to the ...
The investment narrative surrounding Novo Nordisk is undergoing a significant shift. After years of soaring expectations fueled by its obesity and diabetes t ...
U.S. Olympians Elana Meyers Taylor and Gabby Thomas participated in a social video, drawing a throughline between their ...
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
The Huntsville Planning Commission voted to rezone 73.40 acres east of Greenbrier Road and north of Interstate 565 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results